持续使用氯吡格雷对颈动脉内膜切除术患者结局的影响
单机构回顾性分析2010至2017年1066例颈动脉内膜切除术患者,氯吡格雷使用率从31.9%升至56.8%,年增11%(95%CI 6%-15%)。氯吡格雷使用与术后出血(P=.59)或其他并发症(P=.15)无显著关联,作者认为术前不应停用氯吡格雷。
要点
- 氯吡格雷使用率从2010年31.9%升至2017年56.8%,年增11%(95%CI 6%-15%)。
- 术后卒中总发生率1.4%(15/1066),多数为轻度(12/15;80%)。
- 氯吡格雷使用与术后出血(P=.59)或其他并发症(P=.15)无显著关联。
核心结论
- 在本中心的颈动脉内膜切除术实践中,氯吡格雷使用随时间增加,且与术后并发症(包括出血)风险增加无关。
- 作者认为氯吡格雷不应在颈动脉内膜切除术前停用,并应被视为接受颈动脉内膜切除术患者最佳药物治疗的一部分。
研究设计与样本
- 单机构、回顾性研究,基于前瞻性数据库,纳入2010至2017年连续1066例颈动脉内膜切除术患者(中位年龄73岁;66%为男性)。
主要发现
- 手术指征包括≥70%无症状狭窄(458例;43%)、既往卒中(314例;29%)、短暂性脑缺血或视网膜缺血(294例;28%)。
- 术前用药:509例(48%)单用阿司匹林,441例(41%)使用氯吡格雷(374例联合阿司匹林,67例单用),83例(8%)无抗血小板药物记录,33例(3%)使用华法林(国际标准化比值达标)。
- 有症状颈动脉疾病史患者术中氯吡格雷使用可能性更高(P=.002)。
- 氯吡格雷使用率从2010年31.9%升至2017年56.8%,相当于每年增加11%(95%CI 6%-15%)。
- 术后卒中15例(总发生率1.4%),其中12/15(80%)为轻度;单用阿司匹林组6/509(1.2%),氯吡格雷联合阿司匹林组2/441(0.5%),单用氯吡格雷组2/67(2.9%),无抗血小板药物记录组3/83(3.6%),华法林组2/33(6.1%,其中1例为出院30天内致命性颅内出血)。
临床怎么用
- 作者认为,基于这些数据,氯吡格雷不应在颈动脉内膜切除术前停用,并应被视为接受颈动脉内膜切除术患者最佳药物治疗的一部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate the use of clopidogrel at the time of carotid endarterectomy (CEA) and its association with postoperative complications. METHODS: Single-institution, retrospective review of a prospective database. RESULTS: From 2010 to 2017, CEA was performed in 1066 consecutive patients (median age, 73 years; 66% men). The indications for operation included ≥70% asymptomatic stenosis (458; 43%), prior stroke (314; 29%), and transient cerebral or retinal ischemia (294; 28%). At the time of operation, 509 (48%) patients were taking aspirin alone, 441 (41%) were taking clopidogrel (374 in combination with aspirin, 67 as sole therapy), 83 (8%) were on no documented antiplatelet medication, and 33 (3%) were taking warfarin (with therapeutic international normalized ratio). The likelihood of clopidogrel use at the time of operation was higher for patients with a history of symptomatic carotid disease (P = .002). Over the study period, clopidogrel use increased from 31.9% in 2010 to 56.8% in 2017, which corresponds to an 11% (95% confidence interval, 6%-15%) increase annually. Postoperative strokes occurred in 15 patients (overall incidence, 1.4%), the majority of which were minor (12/15; 80%). Six strokes occurred in patients taking aspirin alone (6/509; 1.2%), two in patients on clopidogrel and aspirin (2/441; 0.5%), two in patients taking clopidogrel alone (2/67; 2.9%), three in patients on no documented antiplatelet medication (3/83; 3.6%), and two in those taking warfarin (one of which was secondary to a fatal intracranial hemorrhage within 30 days of discharge [2/33; 6.1%]). The 30-day mortality rate was 0.03% (3/1066); the risk for the combined endpoint of any stroke, death, or myocardial infarction (MI) was 2.3% (25/1066), and the risk for major stroke, death, or MI was 1.2%. There was no apparent association between clopidogrel use and the incidence of postoperative bleeding (P = .59) or any other postoperative complication (stroke, death, MI, cranial nerve injury; P = .15). CONCLUSIONS: Clopidogrel use in our CEA practice has increased over time and has not been associated with an increased risk of postoperative complications, including bleeding. These data suggest that clopidogrel should not be discontinued prior to CEA and should be considered as part of 'optimal medical therapy' in patients undergoing CEA.
引用
- Manunga J, Pedersen C, Stanberry L, et al. Impact of continued clopidogrel use on outcomes of patients undergoing carotid endarterectomy. J Vasc Surg. 2023. PMID: 37086820. doi:10.1016/j.jvs.2023.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。